Read More Pharma Industry News Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy. byVenkateshDecember 6, 2025